Search details
1.
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Breast Cancer Res
; 22(1): 87, 2020 08 12.
Article
in English
| MEDLINE | ID: mdl-32787886
2.
The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer.
Nat Struct Mol Biol
; 31(3): 498-512, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38182927
3.
Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.
Breast Cancer Res
; 13(2): R36, 2011 Apr 01.
Article
in English
| MEDLINE | ID: mdl-21457548
4.
DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity.
Cell Rep
; 36(12): 109722, 2021 09 21.
Article
in English
| MEDLINE | ID: mdl-34551299
5.
The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.
Nat Med
; 27(2): 310-320, 2021 02.
Article
in English
| MEDLINE | ID: mdl-33462444
6.
A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexes.
Nat Commun
; 9(1): 2311, 2018 06 13.
Article
in English
| MEDLINE | ID: mdl-29899353
7.
Clinical Overview of MDM2/X-Targeted Therapies.
Front Oncol
; 6: 7, 2016.
Article
in English
| MEDLINE | ID: mdl-26858935
8.
Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle.
Cell Cycle
; 13(20): 3302-11, 2014.
Article
in English
| MEDLINE | ID: mdl-25485510
9.
Defective decatenation checkpoint function is a common feature of melanoma.
J Invest Dermatol
; 134(1): 150-158, 2014 Jan.
Article
in English
| MEDLINE | ID: mdl-23842115
10.
A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer.
Neoplasia
; 13(2): 154-66, 2011 Feb.
Article
in English
| MEDLINE | ID: mdl-21403841
Results
1 -
10
de 10
1
Next >
>>